BackHarmony Biosciences Holdings Overview
Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Target Price

See Harmony Biosciences Holdings's analyst price targets ($46) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$39.64

Average Target Price

$46.1316.4% upside

8 analysts in the last 4 months

High: $70 | Low: $34

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-01Deutsche Bank$426% upsideOpen
2026-08-26Wolfe ResearchRudy Li$6051.4% upsideOpen
2026-08-05UBS$376.7% downsideOpen
2026-08-05Deutsche Bank$391.6% downsideOpen
2026-08-05Truist FinancialDanielle Brill$3414.2% downsideOpen
2026-08-04OppenheimerAndreas Argyrides$7076.6% upsideOpen
2026-08-03Mizuho Securities$5128.7% upsideOpen
2026-06-30Deutsche BankDavid Hoang$369.2% downsideOpen
2026-02-23Deutsche Bank$3121.8% downsideOpen
2026-02-19Mizuho Securities$5026.1% upsideOpen
2026-02-11UBSYoun Shim$4616% upsideOpen
2026-01-08Truist Financial$4513.5% upsideOpen
2025-12-01Mizuho Securities$4616% upsideOpen
2025-11-24OppenheimerAndreas Argyrides$6256.4% upsideOpen
2025-10-29Mizuho Securities$369.2% downsideOpen
2025-10-15UBS$438.5% upsideOpen
2025-09-25H.C. Wainwright$5538.7% upsideOpen
2025-07-10Goldman SachsCorinne Johnson$3316.8% downsideOpen
2025-04-28UBS$4821.1% upsideOpen
2024-10-30Goldman SachsCorinne Jenkins$2829.4% downsideOpen
2024-10-10Mizuho SecuritiesGraig Suvannavejh$5231.2% upsideOpen
2024-09-10UBSAshwani Verma$5641.3% upsideOpen
2024-08-08Mizuho SecuritiesGraig Suvannavejh$426% upsideOpen
2024-06-24OppenheimerFrancois Brisebois$5641.3% upsideOpen
2024-05-01NeedhamAmi Fadia$5231.2% upsideOpen
2024-04-30Raymond JamesDanielle Brill$376.7% downsideOpen
2022-10-14JefferiesChris Howerton$6153.9% upsideOpen

Harmony Biosciences Holdings (HRMY) FAQ

Harmony Biosciences Holdings (HRMY) currently reports a target price of $46. Use the charts on this page to explore Harmony Biosciences Holdings's target price history and peer comparisons.

Analysts' average 12-month price target for Harmony Biosciences Holdings is $46, about 16.4% upside from the current share price of $39.64. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $46, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Harmony Biosciences Holdings, and consider following HRMY for alerts when major investors trade the stock.

Harmony Biosciences Holdings is classified in the Healthcare sector. On target price, it currently shows $46. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HRMY with unrelated industries.